8-K
filed May 17, 2024, 7:59 PM ET
CIK 0001505512
other material
confidence high
sentiment neutral
materiality 0.60
Regulus shareholders approve 2019 Equity Plan amendment adding 9.5M shares
Regulus Therapeutics Inc.
- Amendment increases share reserve by 9.5M shares; total authorized now 18,574,542.
- Vote: 32,563,555 for, 5,916,084 against, 29,301 abstentions, 3,688,130 broker non-votes.
- Automatic annual increase formula changed to include shares from convertible preferred and prefunded warrants.
- All 10 director nominees elected; say-on-pay approved; Ernst & Young ratified as auditor.
- Non-binding say-on-pay frequency set at one year, consistent with board recommendation.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Regulus Therapeutics Inc. shareholders approved Advisory vote on executive compensation at the 2024-05-16 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2024-05-16
Exact text from the filing
Proposal 3. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement for the Annual Meeting. Votes For Votes Against Abstentions Broker Non-Votes 38,219,586 223,139 66,215 3,688,130
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Regulus Therapeutics Inc. shareholders approved Ratification of Ernst & Young LLP as independent auditor for fiscal year 2024 at the 2024-05-16 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-05-16
Exact text from the filing
Proposal 2. The Company’s stockholders ratified the selection by the audit committee of the board of directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. Votes For Votes Against Abstentions 42,040,910 152,439 3,721
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Regulus Therapeutics Inc. shareholders approved Advisory vote on frequency of say-on-pay votes at the 2024-05-16 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2024-05-16
Exact text from the filing
Proposal 4. The Company’s stockholders approved, on an advisory basis, every year as the preferred frequency for holding stockholder advisory votes on the compensation of the Company’s named executive officers. One year Two Years Three Years Abstentions Broker Non-Votes 38,380,997 10,261 36,660 79,471 3,688,130
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Regulus Therapeutics Inc. shareholders approved Approval of amendment to 2019 Equity Incentive Plan at the 2024-05-16 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2024-05-16
Exact text from the filing
Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Regulus Therapeutics Inc. shareholders approved Election of ten directors at the 2024-05-16 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-16
Exact text from the filing
Proposal 1. Election of Directors The ten persons listed below were elected as directors at the Annual Meeting, each to serve until the Company’s 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. Votes For Votes Withheld Broker Non-Votes David Baltimore, Ph.D. 38,149,013 359,927 3,688,120
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.